Outcomes in Femoropopliteal Disease Stratified by Translesional Pressure Gradient

Peripheral Arterial Disease Clinical Trial

Official title:

Outcomes in Femoropopliteal Disease Stratified by Translesional Pressure Gradient

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02387658
• Other study ID #: Dallas VA IRB Protocol #14-076
• Status: Completed
• Start date: February 6, 2015
• Est. completion date: July 13, 2016

Study information

• Verified date: September 2018
• Source: North Texas Veterans Healthcare System
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

1. To perform an observational analysis to determine if mean translesional gradient measurements (TLG) are associated with differences in clinical outcomes in patients with femoropopliteal arterial disease and claudication.

2. Hypothesis: Patients stratified by a residual translesional gradient </= 11 mmHg after peripheral revascularization or angiography alone will have better clinical outcomes than patients with TLG > 11 mmHg as assessed by six minute walk (6MW), walking impairment questionnaire scores (WIQ), ankle brachial index and need for repeat procedure at 6 months.

Description:

The role of measuring translesional pressure gradients(TLG) in peripheral arterial disease lesions below the iliac artery is unclear. In a previous study the investigators demonstrated that a pressure wire can be effectively used to measure gradients in the femoropopliteal (FP) arterial bed showing good correlation between TLGs recorded with exercise ankle brachial index and walking impairment scores. However there is a no evidence that effectively modifying the gradient or having a high residual gradient after revascularization or just with medical therapy correlates with worse clinical outcomes.

This is a prospective, single center, observational clinical study to evaluate whether measurement of mean residual TLG at the time of angiography and/or immediately after endovascular revascularization are associated with clinically important outcomes in patients with claudication symptoms.

Prior to angiography they will be asked to complete an ankle brachial index evaluation, baseline six minute walk test and walking impairment questionnaire. Arterial access should be obtained in the contralateral common femoral artery to the symptomatic limb if feasible. Angiographic images are to be obtained, interpreted and clinical decisions regarding endovascular treatment are to be made per treating physician's discretion prior to obtaining translesional pressure gradients. In patients whose angiogram does not meet exclusion criteria and do not have a chronic total occlusion (CTO) a baseline TLG will be obtained. A 0.014" pressure wire/catheter to measure pressure will be inserted. After baseline calibration in the superficial femoral artery, the wire will be inserted past the narrowest lesion into the popliteal vessel. Intra-arterial adenosine 100-200 mcg will be given for hyperemia and measurements are to be recorded. If an intervention is planned, repeat measurements are to be obtained at the end of the procedure. If no intervention is planned this will be the residual or final TLG recorded. If baseline measurement are unable to obtained due to a CTO then only a post intervention residual TLG will be obtained and included in analysis. The operator will be blinded to the pre and post TLG measurements by turning the display monitor away from the procedure table and towards the recorder situated in the procedure room when measurements are being obtained.

Patients will follow up within two weeks post angiography for routine scheduled follow up and will obtain repeat ABI, WIQ, and six minute walk if they underwent revascularization. Treating physicians and study coordinators collecting these test measurements will be blinded to TLG measurements but not to angiography and treatment. Patients will again be evaluated at 6 months follow up with repeat ABI, WIQ and six minute walk.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 25
• Est. completion date: July 13, 2016
• Est. primary completion date: July 13, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Signed informed consent

• At least 18 years old

• Unilateral lower limb claudication Rutherford class 2-4

• Subjects must be able to complete screening six minute walk, walking impairment questionnaire, and baseline ankle brachial index

• Estimated survival =1 year in the judgment of the primary operator

• Documented symptomatic femoropopliteal (FP) atherosclerotic disease with at least moderate angiographic stenosis in the symptomatic lower extremity

• Subjects with multilevel disease can be screened and enrolled after treatment of other non FP PAD

Exclusion Criteria:

• Life expectancy less than 12 months or other medical co-morbid condition(s) that could limit the subject's ability to participate in the trial, limit the subject's compliance with the follow-up requirements, or impact the scientific integrity of the trial

• Severe Bilateral claudication

• Known hypersensitivity or contraindication to contrast dye that, in the opinion of the investigator, cannot be adequately pre-medicated

• Known hypersensitivity to adenosine or moderate to severe asthma

• Pregnancy

• Serum Creatinine >2.5

• Vascular graft, aneurysm or postsurgical stenosis of the target vessel

• Documented untreated severe iliac or below-the knee stenosis with < 2 vessel run-off in leg with femoropopliteal stenosis or untreated bilateral symptomatic peripheral arterial disease

Related Conditions & MeSH terms

• Claudication
• Intermittent Claudication
• Peripheral Arterial Disease
• Peripheral Vascular Diseases

Intervention

Procedure:
• translesional gradient measurement
Patients will be stratified into two groups based on the final mean translesional pressure gradient obtained in the femoropopliteal arterial bed after revascularization or just after angiography if no revascularization is done.

Locations

Country	Name	City	State
United States	VA North Texas Health Care System	Dallas	Texas

Sponsors (1)

Lead Sponsor	Collaborator
North Texas Veterans Healthcare System

Country where clinical trial is conducted

United States, 

References & Publications (8)

Archie JP Jr. Analysis and comparison of pressure gradients and ratios for predicting iliac stenosis. Ann Vasc Surg. 1994 May;8(3):271-80. — View Citation

Banerjee S, Badhey N, Lichtenwalter C, Varghese C, Brilakis ES. Relationship of walking impairment and ankle-brachial index assessments with peripheral arterial translesional pressure gradients. J Invasive Cardiol. 2011 Sep;23(9):352-6. — View Citation

Belch JJ, Topol EJ, Agnelli G, Bertrand M, Califf RM, Clement DL, Creager MA, Easton JD, Gavin JR 3rd, Greenland P, Hankey G, Hanrath P, Hirsch AT, Meyer J, Smith SC, Sullivan F, Weber MA; Prevention of Atherothrombotic Disease Network. Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med. 2003 Apr 28;163(8):884-92. Review. — View Citation

De Bruyne B, Manoharan G, Pijls NH, Verhamme K, Madaric J, Bartunek J, Vanderheyden M, Heyndrickx GR. Assessment of renal artery stenosis severity by pressure gradient measurements. J Am Coll Cardiol. 2006 Nov 7;48(9):1851-5. Epub 2006 Oct 17. — View Citation

Garcia LA, Carrozza JP Jr. Physiologic evaluation of translesion pressure gradients in peripheral arteries: comparison of pressure wire and catheter-derived measurements. J Interv Cardiol. 2007 Feb;20(1):63-5. — View Citation

Klein AJ, Pinto DS, Gray BH, Jaff MR, White CJ, Drachman DE; Peripheral Vascular Disease Committee for the Society for Cardiovascular Angiography and Interventions. SCAI expert consensus statement for femoral-popliteal arterial intervention appropriate use. Catheter Cardiovasc Interv. 2014 Oct 1;84(4):529-38. doi: 10.1002/ccd.25504. Epub 2014 Jun 12. — View Citation

Tetteroo E, van Engelen AD, Spithoven JH, Tielbeek AV, van der Graaf Y, Mali WP. Stent placement after iliac angioplasty: comparison of hemodynamic and angiographic criteria. Dutch Iliac Stent Trial Study Group. Radiology. 1996 Oct;201(1):155-9. — View Citation

Walker C. What is the role of translesional pressure gradient measurement in peripheral intervention? J Invasive Cardiol. 2011 Sep;23(9):357. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Secondary analysis evaluating correlation between change in 6 minute walk distance at 6 month and residual translesional gradients.	evaluate for linear correlation between change in six minute walk from baseline to 6 months to mean translesional gradient	6 months
Other	Secondary analysis evaluating correlation in change in WIQ score at 6 month and residual translesional gradients.	evaluate for linear correlation between change in WIQ from baseline to 6 months to mean translesional gradient	6 months
Primary	Change in six minute walk distance in meters at 6 months	Compare change in six minute walk distance at 2 weeks post angiography +/- revascularization to distance walked at 6 months +/- 15 days between patients stratified by a residual mean translesional gradient > 11 mmHg or	6 months +/- 15 days after enrollment
Secondary	Change Walking Impairment Questionairre (WIQ)Score at 6 months	Compare change in WIQ scores from within 2 weeks post angiography +/- revascularization to WIQ score at 6 months +/- 15 days between patients stratified by a residual mean translesional gradient > 11 mmHg or	6 months +/- 15 days after enrollment
Secondary	Change in Ankle Brachial Index (ABI) at 6 months	Change in ABI between patients stratified by a residual mean translesional gradient > 11 mmHg or	6months +/- 15 days after enrollment
Secondary	Change in six minute walk distance from baseline to within 2 weeks post revascularization	Change in six minute walk from baseline measurement in those patients that undergo revascularization to six minute walk distance checked within 2 weeks after revascularization.	baseline pre revascularization to two weeks post measurement
Secondary	Change in WIQ score from baseline to within 2 weeks post revascularization	Change in WIQ score from baseline measurement in those patients that undergo revascularization to six minute walk distance checked within 2 weeks after revascularization.	baseline pre revascularization to two weeks post measurement
Secondary	Need for repeat revascularization or amputation as assessed by rates of need in repeat revascularization or amputation	compare rates of need in repeat revascularization or amputation between patients stratified by a residual mean translesional gradient > 11 mmHg or	six months